Document is current
Any future updates will be listed below
-
Authors
Yang, Jinsong
Huang, Ai
Yang, Kunyu
Jiang, Ke
-
Funding
Funding for this research was provided by:
BeiGene
- License Information
-
More Information
Article History
Received: 5 October 2022
Accepted: 27 February 2023
First Online: 15 March 2023
Declarations
:
: This study protocol was approved by the ethics committee of the Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China on January 26, 2021 (2020–0375-02). The authors state that the study will be performed in accordance with the Declaration of Helsinki, the ethical principles of the Good Clinical Practice guidelines, and the principles of informed consent. Written informed consent will be obtained from each patient prior to enrollment. This manuscript was prepared according to the SPIRIT guidelines.
: Not applicable.
: This study is an investigator-initiated trial and the study medication (tislelizumab) was externally funded by BeiGene, Ltd. The authors declare that they have no competing interests.
